Medicare AdvantagePrior AuthMedium impact
MA08.073u, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology, Pharmacy·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
This recent policy (effective 01/01/2026) updates medical necessity criteria for intravitreal injections of VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors used to treat retinal conditions. Billing teams must review and implement new authorization requirements and documentation standards for these pharmacy-administered therapies to ensure claim approval.
Action Required
By 01/01/2026: Billing and clinical teams must obtain and review the complete MA08.073u policy text from the source URL to identify specific medical necessity criteria, prior authorization requirements, and documentation standards for intravitreal VEGF antagonist injections. Update billing system authorization workflows and provider order entry templates to enforce new criteria. Verify which specific HCPCS codes (likely J-codes for biologics and combination therapies) fall under revised requirements and configure claim submission rules accordingly. Communicate updated requirements to ophthalmology and retina specialists. Failure to comply with new medical necessity criteria will result in claim denials.